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RESULTS: A total of six systematic reviews (SR) were found and met our inclusion 
criteria. For the indolent indication: a) Wake et al. 2002 and Schulz et al. 2007 evalu-
ated the treatment as ﬁrst line or subsequent therapies; b) Vidal et al. 2009 and Aksoy 
et al. 2009 assessed the maintenance therapy; c) Cheung et al. 2007 evaluated: ﬁrst 
line and subsequent therapies, maintenance and aggressive NHL; and d) Knight et al. 
2004 evaluated aggressive NHL. Only three studies developed a meta-analysis (Vidal, 
Schulz and Aksoy). According to the SRs rituximab induced remission, improved 
overall survival and disease control. Twenty ﬁve HTAR were found: 5 indicated the 
analysis through inexistent links; 2 belonged to sites with content blocked to non-
members; 2 related to other drugs; 3 indicated ongoing analysis; 3 related to other 
indications. Consequently, 10 reports met the survey criteria. Seven out of 10 pub-
lished HTAR support the use of rituximab for indolent or aggressive lymphomas. 
There are three assessments which are not conclusive. CONCLUSIONS: Findings from 
systematic reviews suggest that rituximab offer better clinical outcomes to patients. 
Most of the Health Technology Assessment reports indicate rituximab as a cost-
 effective alternative.
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OBJECTIVES: The use of Trastuzumab (T) for the adjuvant treatment of breast cancer 
patients (BCP) has been tested in clinical trials. Our goal is to perform a health tech-
nology evaluation in order to stablish if the scientiﬁc evidences are strong enough to 
support the use of T and to compare its cost-effectiveness ratio (CER) with other 
treatments covered by the public sector in Brazil. METHODS: We performed a litera-
ture search, looking for randomized controlled clinical trials (RCTs), systematic 
reviews (SR), guidelines, pharmacoeconomic analysis and endorsements from regula-
tory agencies on the use of T for BCP. RESULTS: We found ﬁve RCTs, three SR, six 
guidelines / health technology assessments and three endorsements from regulatory 
agencies. Four RCTs tested Trastuzumab 2 mg/kg/week or 6 mg/kg/ every 3 weeks 
during one year, in patients with tumors  1 cm. All of these showed a 50% reduction 
on risk of relapse and a 40% reduction in death risk. SR conﬁrmed these ﬁndings. 
The only study that did not show a survival gain, used T for only nine weeks. Guide-
lines and regulatory agencies recomend the use of T for one year. On the pharmaco-
economic perspective, T has a CER similar or better than other procedures covered 
by the public sector in Brazil, such as heart transplant, tacrolimus for kidney trans-
plantation, ribavirin plus peg-interferon for C hepatitis and bone marrow transplant. 
These procedures have a CER betwen US$35,000 and US$45,000 / QALY (or above). 
The CER of adjuvant T is around US$20,000/QALY. CONCLUSIONS: Trastuzumab 
is indicated for the adjuvant treatment of BCP, and must be considered as standard 
treatment for these patients. Also, from a pharmacoeconomic point of view, it’s CER 
is similiar to other medical interventions covered by the Brazilian health care public 
system.
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OBJECTIVES: To conduct a review of the Health Technology Assessments (HTA) 
recommendations published on the International Network of HTA (INAHTA) website 
concerning the use of capecitabine to treat colorectal cancer in order to support the 
decision making in Brazil. METHODS: A search was conducted on INAHTA website 
(www.inahta.org), in English language, for the key word “capecitabine”. Nineteen 
results were found, from which: 5 referred to other drugs; 6 to other capecitabine 
indication; 1 indicated an ongoing analysis, consequently, 7 results met our objective. 
RESULTS: The economic assessments found were conducted in Europe (6) and Argen-
tina (1). All reports positively recommended the use of capecitabine. In the metastatic 
setting, the assessment made in 2003 by the NHS of Scotland and NICE (England) 
recommended capecitabine as an option for ﬁrst line monotherapy; that of the NIHR 
Health Technology Assessment programme (England, 2003) showed that there are 
cost savings associated with the use of capecitabine and that of the IECS (Argentina, 
2004), concluded that capecitabine could be a therapeutic option with an easier 
administration and better safety proﬁle. In the adjuvant setting, the NHSC (England, 
2003) assessed that capecitabine may have a signiﬁcant beneﬁcial impact on patients, 
health services and staff. In 2006, NICE recommended capecitabine as monotherapy 
for patients with stage III (Dukes’ C) colon cancer following surgery and the NIHR 
Health Technology Assessment programme showed that capecitabine is cost-effective 
in comparison with 5-FU/LV regimens. The authors also suggested that further 
research is necessary to compare effectiveness of capecitabine with other 5-FU/LV 
infusion regimens common used. CONCLUSIONS: According to this review, all 
published economic assessments up to the present date support the use of capecitabine 
for colorectal cancer (metastatic and adjuvant therapy).
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OBJECTIVES: To conduct a review of Health Technology Assessments (HTA) recom-
mendations published on the International Network of HTA (INAHTA) website 
concerning use of capecitabine to treat breast cancer in order to support decision 
making in Brazil. METHODS: A search was conducted on INAHTA website (www.
inahta.org), in English language, for the key word “capecitabine”. Nineteen results 
were found, from which: 5 referred to other drugs; 10 to other capecitabine indica-
tions; consequently, 4 results met our objective. RESULTS: The economic assessments 
found were conducted in Europe (3) and Argentina (1). From these, 3 positively recom-
mend the use of capecitabine for breast cancer and 1 did not state a clear recommenda-
tion, though considering that capecitabine seems to be a cost-effective therapy. The 
analysis conducted in 2003 by the NHS of Scotland for metastatic breast cancer, 
and that of the NICE (England) for locally advanced or metastatic breast cancer were 
replaced by NICE guidance CG81 (2009), which recommended capecitabine as mono-
therapy for second or third line in patients for whom anthracycline-containing 
regimens are unsuitable or have failed. In 2004, the IECS(Argentina), concluded 
that capecitabine can be a therapeutic option for locally advanced or metastatic 
breast cancer combined with docetaxel or as monotherapy. The assessment stated 
that capecitabine should be used when patients failed or are not eligible for anthracy-
cline-containing regimens. The assessment by NIHR Health Technology Assessment 
programme (England, 2004), indicated that capecitabine treatment as monotherapy 
or combined with docetaxel for locally advanced and/or metastatic breast cancer 
appears to be cost-effective. However, the authors stated that the evidence base 
for assessment was poor and further investigation is necessary. CONCLUSIONS: 
According to this review, the published economic assessments up to the present 
date suggest capecitabine as an option for the treatment of breast cancer (locally 
advanced or metastatic) for patients who failed or are not eligible for anthracycline-
containing regimens.
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OBJECTIVES: Since 2004, hospital cares are ﬁnanced by allotted amounts at a 
speciﬁc diagnosis-based level. In order to guarantee access to innovative drugs, high-
cost drugs are gathered on a positive list and are paid out of the budget with a total 
reimbursement under conditions of good use. As hospital drugs prices are free, the 
regulator sets up a reimbursement price cap in 2005, named responsibility tariff (RT), 
to avoid uncontrolled increase of prices due to a low interest in negotiation between 
hospitals and ﬁrms. The aim of this work is to assess the impact of this regulation 
measure on cancer drugs market between 2004 and 2007. METHODS: This study 
uses data from the technical agency of information on hospitals and included establish-
ments previously under ﬁxed global budget. Those data, from 2004 to 2007, provide 
quantities, expenditures and purchase prices of cancer drugs on this list belonging to 
the L01 level of the world health organization anatomical therapeutic and chemical 
classiﬁcation. Furthermore, an index representing the ratio of the purchase prices 
and the RT is built. RESULTS: The consumption of L01 drugs shows an important 
evolution with a 17.2% yearly growth rate between 2005 and 2007. Expenditures 
exceed 1.6 billions of euros in 2007. The contribution of L01 in spending of the high-
cost drugs list reaches 66% in 2006 and 37% in 2007. The RT leads to a transient 
prices decrease in 2005 before an alignment on regulated prices. Only competitive 
market allows low prices under RT. CONCLUSIONS: The rising spending of cancer 
drugs is due to the consumption of recent and expensive drugs. Their rationalization 
implies a strict innovation evaluation. The optimal level of innovation still needs to 
be deﬁned.
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OBJECTIVES: Due to wide variations in prescribing practice, a key methodological 
challenge for an economic analysis in oncology is describing current practice. Robust 
methods of eliciting the full range of expert opinion are necessary to ensure clinical 
relevance and validity of economic models. Insufﬁcient information about variations 
in management can lead to model underestimation of uncertainty. This study aims to 
determine the appropriate model structure for an economic evaluation of a pharma-
cogenetic test to inform irinotecan prescribing, by identifying current practice. 
METHODS: Expert opinion was elicited to inform model structure. Through semi-
structured postal survey (May-August 2008), clinical experts were asked to describe: 
the general management of advanced CRC patients on chemotherapy, place of irino-
tecan-based regimens within the clinical pathway and management of patients on these 
regimens. Since data on the frequency of key adverse events (neutropaenia and 
